Researchers at Baylor College of Medicine and collaborating institutions have uncovered a key molecular player that is ...

Pulmonary fibrosis (PF) is a progressive interstitial lung disease (ILD) characterized by excessive fibrotic tissue deposition in the pulmonary parenchyma. The term "pulmonary" refers to the lungs, ...

Forced oscillation technique (FOT) can enhance early detection and management of progressive pulmonary fibrosis.

Preclinical data demonstrate ATYR0101’s unique anti-fibrotic mechanism through interaction with LTBP-1. ATYR0101 to be showcased in oral presentation at the American Thoracic Society (ATS) 2025 ...

The combination of antifibrotic therapy and pulmonary vasodilator therapy improved transplant-free survival but had no ...

Pliant Therapeutics will cut 45% of its workforce in a sweeping restructuring effort aimed at extending its cash runway, the biotech disclosed after market close on 1 May. The move comes just weeks ...

SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of ...

We look forward to further exploring this candidate in pulmonary ... lung and kidney fibrosis suggesting it may have broad therapeutic potential in multiple fibrotic diseases. ATYR0101 is currently ...

(MENAFN- GlobeNewsWire - Nasdaq) Preclinical data demonstrate ATYR0101's unique anti-fibrotic mechanism through interaction with LTBP-1. ATYR0101 to be showcased in oral presentation at the ...

Preclinical data demonstrate ATYR0101's unique anti-fibrotic mechanism through interaction with LTBP-1. ATYR0101 to be showcased in oral presentation at the American Thoracic Society (ATS) 2025 ...